AllDocs -> cancers

Colon cancer data set (Alon et al., 1999): statistical significance tests on test set ROC area experiments 1 2 3 4 5 6 7 8 9 1 1.000000 0.859650 0.000059 0.513192 0.135862 0.513192 0.211331 0.454919 0.000068 2 0.859650 1.000000 0.000059 0.726978 0.098283 0.726978 0.143702 0.395416 0.000059 3 0.000059 0.000059 1.000000 0.000059 0.000059 0.000059 0.000059 0.000059 0.986130 4 0.513192 0.726978 0.000059 1.000000 0.098547 1.000000 0.156365 0.090576 0.000069 5 0.135862 0.098283 0.000059 0.098547 1.000000 0.098547 1.000000 0.985101 0.000069 6 0.513192 0.726978 0.000059 1.000000 0.098547 1.000000 0.156365 0.090576 0.000069 ...

Colon cancer data set (Alon et al., 1999): statistical significance tests on validation set LOO-CV per- formance experiments 1 2 3 4 5 6 7 8 9 1 1.000000 0.425781 0.000058 0.001113 0.128135 0.001113 0.192185 0.000167 0.000054 2 0.425781 1.000000 0.000058 0.000854 0.180288 0.000854 0.283767 0.000155 0.000054 3 0.000058 0.000058 1.000000 0.000057 0.000058 0.000057 0.000058 0.000057 0.000036 4 0.001113 0.000854 0.000057 1.000000 0.056524 1.000000 0.044549 0.001953 0.000079 5 0.128135 0.180288 0.000058 0.056524 1.000000 0.056524 1.000000 0.000703 0.000082 6 0.001113 0.000854 0.000057 1.000000 0.056524 1.000000 0.044549 0.001953 ...

A S P I R E Foundation, Inc. Cancer The Community Hospital R ESEARC H For the Prevention, Diagnosis and Treatment of Cancer Volume 2 Issue 2 Summer 2002 Colon Cancer : Focus on Detection & Prevention New initiative seeks to reduce incidence of colon cancer stronger by the support of local Cancers of the colon and The Community Hospital community groups such as rectum are the second leading Cancer Research Foundation, Ahepa, the Daughters of cause of cancer deaths in the with Community Healthcare Penelope, the John W. U.S. At least one third of deaths System, has launched a year- Anderson Foundation,” said from colon cancer could be long initiative to raise Donald S. Powers, Chairman avoided if everyone ...

45 Retinol inhibits the growth of Retinoic Acid-resistant colon cancer cells Presenter Jessica Leland Collaborators Professor Michelle Lane, Alice Dillard, and Erik Wilder, Department of Human Ecology Department Nutrition Abstract Retinoids, derivatives of Vitamin A, are responsible for inducing differentiation and inhibiting cell growth in colon cancer . Retinoic Acid (RA) is unable to inhibit the growth of cells that become RA-resistant through alteration in metabolism or the loss of retinoic acid or retinoic “X” receptor activity. We investigated the ability of the more physiologically relevant retinoid, retinol, to inhibit the growth of RA-resistant colon cancer cell lines, determined the bioactive metabolites produced within these cells, and the mechanism by which growth is inhibited. HCT-116, SW620, and WiDr cells were treated with 0 (control), ...

P.O.Box 2345, Beijing 100023,China World J Gastroenterol 2003;9(2):281-283 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2003 by The WJG Press ISSN 1007-9327 • COLORECTAL CANCER • Effects of TNP-470 on proliferation and apoptosis in human colon cancer xenografts in nude mice Zong-Hai Huang, Ying-Fang Fan, Hu Xia, Hao-Miao Feng, Fu-Xiang Tang Zong-Hai Huang, Ying-Fang Fan, Hao-Miao Feng, Fu-Xiang Tang, Department of Surgery, Zhujiang Hospital, First Military Medical university, Guangzhou 510282, Guangdong Province, China Hu Xia, Department of Respiratory Diseases, Zhujiang Hospital, First Military Medical University, Guangzhou 510282, Guangdong Province, China Supported by the Natural Science Foundation of Guangdong Province, No.013072 Correspondence to: Dr. Zong-Hai Huang, ...

O N C O L O G Y S E R V I C E S Teaming Up to Fight Colon Cancer Page 2 Dear Colleagues: Each year in this annual report, we look back at past accomplishments. This year, we are expanding on that idea and are providing information that physicians, clini- cians and the general public can use as well. In this report we study colorectal cancer and share with you Miami Valley Hospital’s approach to fighting this dis- ease. I also want to share with you some highlights from 2002: ¦ Miami Valley Hospital was named one of the US News&World Report’s top 50 hospitals in five categories, including gynecology which focuses on fertility problems and reproductive cancers. Our Gynecologic Oncology Center is the only program of its kind in the Dayton area. Dr. William Nahhas and his staff are to be commended. ¦ The Joint Commission ...

Semi-Automated Imaging of Human and Mouse Colon Neoplasia D. Rannie, R. D. G. Malcomson, L.B. Jordon, D. J. Harrison. Sir Alastair Currie Cancer Research UK Laboratory, Molecular Medicine Centre, Edinburgh EH8 9AG, United Kingdom. INTRODUCTION METHODS IMAGES ASSESSMENT OF DNA CONTENT (PLOIDY) BY IMAGE CYTOMETRY. Aneuploidy within colorectal cancers has been associated with poor prognosis and increased likelihood of local recurrence following resection. Improved methods for the calculation of DNA content by image cytometry are bring new insight into the value of ploidy assessment as an independent prognostic factor in early stage colorectal cancers. Automated microscopy and specifically designed software (Ploidy; Fairfield Imaging) allow for fast and accurate estimation of DNA content. Aim: determine potential as routine clinical ...

FDA Background for Colon Cancer Endpoints Workshop This document provides FDA background information for a November, 2003 public workshop to discuss endpoints for the approval of colon cancer drugs. I. FDA examination of endpoints for cancer drug approval The Food and Drug Administration is soliciting input on what endpoints are acceptable as the basis for cancer drug approval. Endpoints will be examined for the most common cancers, such as lung cancer , colon cancer , etc. For each cancer , FDA will hold public workshops to identify important issues, and these issues will be discussed in meetings of the Oncologic Drugs Advisory Committee (ODAC). Subsequently, guidance documents will be published describing FDA's current thinking on endpoints for cancer drug approval. Workshop planning is guided by a steering committee that includes representation from the FDA, the National Cancer Institute, ...

Abstract. The effects of mono, duple and triple treatment with octreotide, galanin and serotonin on a human colon cancer cell line (SW 620) were investigated. The cancer cells were exposed to a dose corresponding to 20 µ g/kg body weight/day, and to 50 and 25% of this dose (0.2, 0.1 and 0.05 µ g/ml). The cells were observed at the intervals: 3, 6, 12, 24 and 48 h. MTT-assay was used to determine numbers of viable cells. Proliferation and apoptosis were detected by immunocytochemistry using the avidin-biotin complex (ABC) method. The antibodies used were anti-Ki-67, anti- poly (ADP-ribose) polymerase ‘PARP’ and anti-Bcl-x. Proliferative and apoptotic indices were determined by computerized image analysis. Almost all the mono and duple treatments of the bioactive substances succeeded in reducing the numbers of viable cells. With triple treatment, however, this decrease was greater and was evident ...

P.O.Box 2345, Beijing 100023,China World J Gastroenterol 2003;9(9):1976-1980 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2003 by The WJG Press ISSN 1007-9327 • COLORECTAL CANCER • EffectsofDNAmethylationonexpressionoftumorsuppressorgenes and proto-oncogene in human colon cancer cell lines Jing-Yuan Fang, Juan Lu, Ying-Xuan Chen, Li Yang Jing-Yuan Fang, Juan Lu, Ying-Xuan Chen, Li Yang, Shanghai Institute of Digestive Diseases, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, China Supported by the National Natural Science Foundation of China, No.30170413, and Ph.D Funds from the Ministry of Education of China, No.199946, and the Key Subject Funds of Shanghai Education Committee to Jing-Yuan Fang Correspondence to: Dr. Jing-Yuan Fang, Shanghai Institute of ...

351 Braz J Med Biol Res 35(3) 2002 Aberrant crypt foci and colon cancer Brazilian Journal of Medical and Biological Research (2002) 35: 351-355 ISSN 0100-879X Aberrant crypt foci and colon cancer : comparison between a short- and medium-term bioassay for colon carcinogenesis using dimethylhydrazine in Wistar rats Departamento de Patologia, Faculdade de Medicina, Universidade Estadual Paulista, Botucatu, SP, Brasil M.A.M. Rodrigues, L.A.G. Silva, D.M.F. Salvadori, J.L.V. de Camargo and M.R. Montenegro Abstract Aberrant crypt foci (ACF) in the colon of carcinogen-treated rodents are considered to be the earliest hallmark of colon carcinogenesis. In the present study the relationship between a short-term (4 weeks) and medium-term (30 weeks) assay was assessed in a model of colon carcinogenesis induced by dimethylhydrazine (DMH) ...

Abstract. We previously reported that vessel count, vascular endothelial growth factor (VEGF) and platelet derived endo- thelial cell growth factor (PD-ECGF) expression are associated with metastasis formation in human colon cancer . This study was done to determine a stage of colon cancer progression where induction of these factors occurred (i.e. the angiogenic switch). We examined vessel count, VEGF, and matrix metalloproteinase (MMP)-7 expression in cancer cells and PD-ECGF expression in infiltrating cells in 25 adenomas, 35 mucosal cancers (Tis), 29 submucosal invasive cancers (T1) and 33 muscularis propria invasive cancers (T2) by immunostaining. The intensity of staining of VEGF and MMP-7 was evaluated blindly at the invasive edge and was confirmed by image analysis. Intensity of staining for these factors was graded on a scale of 0 to 3+, with 0 representing no detectable stain and ...

Abstract. Telomerase activity, a cardinal requirement for immortalization, is a crucial step in the development of cancer and has been studied in many kinds of malignant tumours for clinical diagnostic and/or prognostic utilities. Using a PCR- based TRAP assay, we investigated telomerase activity in 8 adenomatous polyps, 9 dysplastic polyps, and in 36 paired cancer -normal mucosa specimens, one liver and one spleen metastasis from patients resected for sporadic colorectal cancer . Telomerase was absent or very low in normal mucosa and in adenomatous polyps. Dysplastic polyps and adenocarcinoma samples showed telomerase activity, with higher levels in cancer tissues compared to dysplastic lesions. A high telo- merase activity was shown to be associated with late-staged cancers and metastasis, providing arguments supporting the role of telomerase not only in the development but also in the progression ...

What is FAP? Familial Adenomatous Polyposis (FAP) is an inherited condition in which hundreds to thousands of pre- cancerous or "adenomatous" polyps form in the colon , usually beginning at age 16. People with FAP have almost a 100 percent chance of developing colon cancer in their lifetime. However, if a person with FAP undergoes regular screening (see guidelines on attached card) and proper medical management, colon cancer can almost always be prevented. FAP occurs when there is a mutation or change on a gene called the adenomatous polyposis Randall W. Burt, M.D. Director, Colon Cancer Program, Huntsman Cancer Institute Registry Coordinators Familial Adenomatous Polyposis Spring 2001 What’s Inside: 1-3 Understanding FAP and AAPC 4 Is genetic testing right for your family? ...

at Huntsman Cancer Institute Familial Colon Cancer Registry Everyone is touched by inheritance in some way; you may have been told that you have your father’s smile, your mother’s sense of humor, or your uncle’s nose. It is easy to think of examples when it comes to physical or personality traits. At the Registry, we are in the business of thinking about the inherited nature not of personality or appearance, but of polyps, colon cancer and related cancers. We want to learn more about the causes, prevention, and treatment of cancer by studying syndromes or trends in families like yours. We have invited several groups into the Registry - each will help us focus on different aspects of cancer . The goal of this article is to help you understand the scope of the Registry and how you fit into our resource. What are genes? ...

at Huntsman Cancer Institute Familial Colon Cancer Registry We thank all of you who are considering participation in our Colon Registry. The purpose of the Registry is three-fold: 1) to keep you up to date on the research and advances important to your care; 2) to let you know of research projects that you may be interested in joining; and, 3) to assist in clinical care associated with risk for inherited or familial polyps, colon cancer and related cancers. It is an exciting time in the area of genetics pertaining to cancer . The involved genes are known for many of the inherited cancer syndromes making genetic testing available to determine who does and does not have one of the syndromes. In addition, most cancers in this category can now be prevented through proper screening. We also continue to look at new prevention strategies and therapies. For example, medications that cause ...

Abstract. Voltage-gated potassium channels (VGPCs) have been previously implicated in cellular proliferation. In this study, the expression of VGPCs was examined by immuno- histochemistry in seventy-four human colonic carcinoma specimens. Immunostaining for the Kv1.3 type VGPC was absent in two normal human colon specimens. Kv1.3 staining in the 74 colon cancer specimens was low in 9% (7/74), moderate in 61% (45/74) and high in 30% (22/74). Potassium channel (PC) openers, minoxidil and diazoxide (5-50 µ g/ml), increased growth of SW1116, LoVo, Colo320DM and LS174t human colon cancer cell lines by 20-40%. PC-blockers, dequalinium and amiodarone, caused marked growth- inhibition of the four cell lines, at concentrations between 1 to 3 µ g/ml. PC-blockers such as glibenclamide inhibited cellular proliferation at concentrations above 50 µ g/ml while tetraethylammonium and 4-aminopyridine (up ...

Abstract. Angiogenesis is an essential requirement for the development, progression and metastasis of malignant tumors. Vascular endothelial growth factor (VEGF) plays an essential role in the development of angiogenesis of numerous solid malignancies, including colon cancer . The tumor suppressor gene p53 is a potent transcriptional regulator of genes which are involved in many cellular activities, including cell-cycle arrest, apoptosis and angiogenesis. In order to better understand the relation among p53 status, VEGF expression and microvessels count (MVC) in colon cancer , we evaluated immunoreactivity for CD34 endothelium- associated antigen, VEGF and p53 proteins in 43 cases of colon adenocarcinoma. Our results demonstrated an association between VEGF expression, p53 status and angiogenesis, suggesting that mutant p53 plays a central role in promoting angiogenesis in colon cancer ...

Cancer Services Colon Cancer Screening Program Colon cancer is the number two cause of death from cancer in the United States. About 131,000 men and women will get cancers of the colon this year. Most people get it after age 50. But if you take 10 minutes of your time to screen today, you may save your life tomorrow. Why is it Important to Find Colon Cancer Early? Colon cancer is much easier to cure when found early. By doing so, we can prevent 80% of colon cancer deaths. Finding cancer early could: • Save your life • Avoid later surgeries What if I Feel Just Fine? If you are 50 or older, this is the best time to get a colon cancer screening test. In its early stage, colon cancer does not cause any symptoms or pain. Screening tests help find problems early -- long before you would notice something wrong. What is Done ...

Case #4 Sentinel Node Biopsy in Colon Cancer David M. Ota, MD, FACS Milwaukee, WI Page 2 65 yo female with sigmoid adenoca. CXR, liver US and CEA are normal. Sigmoid colectomy done and final path report shows T3 with 6 negative lymph nodes(T3N0M0). Page 3 Pathologic Understaging of CRC reality or fiction? Page 4 Colon Cancer 5 yr survival stage I 90-95% stage II 80% stage III 50-60% Page 5 Stage II Colon Ca 1016 pts in 5 adjuvant trials 5 yr survival obs 80% FU+LV 82% Impact Invest JCO 1999 Page 6 Stage III improved survival with FU+LV Some Stage II are understaged Page 7 Standard Technique 1. ...

Vol. 8, No. 12 April 19, 2002 Identifying gene variants may help evaluate colon cancer risk Keck School of Medicine oncologists recently took their research on the road, sharing results from their studies on genetic variations and their relationship to colon cancer patients’ outcomes. Heinz-Josef Lenz, associate professor of med- icine, and researchers in his lab at the USC/Norris Comprehensive Cancer Center reported that certain polymorphisms in genes might help direct treatment choices or potential- ly provide a way to tip off people at high risk of developing cancer . The researchers reported their findings at the 93rd annual meeting of the American Association for Cancer Research, held from April 6 to 10 in San Francisco. The investigators are looking into three genes: thymidylate synthase, or TS; glutathione S-transferase P1, or GSTP1; and ...

New Technologies to Improve Cancer Diagnosis and Treatment Breakthroughs in cancer diagnosis and treatment are helping save more patients’ lives than ever before. National Cancer Institute statistics show the cancer death rate is falling by more than 1% each year. Advances in technology are not only saving peoples’ lives but also helping improve the productivity of our health care system and reduce overall costs. Many of these exciting innovations are on display at the National Dialogue on Cancer event Cancer Research: New Technology’s Role in Diagnosis and Treatment. Colon Cancer Colorectal cancer often is diagnosed late and results in death. It is estimated that there will be 138,900 new cases in 2001 with a projected death toll of 57,100. Even though colorectal cancer is most curable if detected in the early stages, many Americans are failing to be screened for colorectal ...

distinguishes this syndrome from another inherited condition, called Familial Adenomatous Polyposis (FAP), in which individuals develop hundreds or thousands of polyps, while people with HNPCC may only develop a small number of polyps. Individuals who have HNPCC have an 80 percent lifetime risk of developing colon cancer . However, it is important to note that not all individuals with HNPCC will develop colon cancer . In HNPCC, colon cancer occurs around age 44, whereas the statistical average for a diagnosis of colon cancer is about age 65. With regular screening (see “Screening Recommendations” on page 3) and appropriate medical management, colon cancer can almost always be prevented. What are colon polyps? Polyps are abnormal growths that form on the inside lining of the by Lisa Bredthauer High Risk Registry Coordinator ...

24 5 Cancer of the colon Summary In 1992–1997 relative survival one year after diagnosis was 77.6% for males and 76.0% for females. Five-year relative survival proportions were 58.3% and 58.7% for males and females, respectively (Table 5.1). Survival ten years after diagnosis was 51.0% for males and 52.0% for females in 1987–1991, the most recent period for which ten-year relative survival data are available (Tables 5.2 and 5.3). Relative survival after diagnosis of colon cancer increased significantly between 1982–1986 and 1992–1997 diagnostic periods. Increases in relative survival have been statistically significant for all relative survival times (including one-, five- and ten- year relative survival) for males and females. Five-year relative survival increased by 8.1 percentage points for males and 7.4 percentage points for females between 1982–1986 and 1992–1997 (Figure 5.2; Tables ...

Genetic testing for colon cancer : Joint statement of the American College of Medical Genetics and American Society of Human Genetics Joint Test and Technology Transfer Committee Working Group Colorectal cancer (CRC) is the second leading cause of can- cer death in the United States. Annually, approximately 130,200 individuals will be diagnosed and 56,300 will die from this disease. 1 In general, CRC evolves in an “adenoma to car- cinoma” sequence during which a series of somatic alterations accumulate in the DNA of the tumor tissue. Since 1987, signif- icant strides have been made in characterizing the genetic events that lead to colorectal cancer . This work has been based on detailed clinical and molecular genetic studies of colorectal tumors. Acquired genetic alterations seen in tumors include APC and MCC on chromosome 5q, KRAS on chromosome 12p, DCC on chromosome ...

Agricultural Research/November 1997 23 Could Wheat Bran Fight Colon Cancer ? It’s long been known that raw wheat bran helps laboratory animals battle colon cancer . Now, ARS scientists and colleagues from Kellogg Co., Battle Creek, Michigan, have teamed up to find out if pro- cessed wheat bran can have a similar effect. Bran is the thin outer layer of the wheat kernel. Processed bran is found in breakfast cereals, whole-wheat breads, and other foods. The new research is being conducted under a cooperative research and develop- ment agreement. Earlier medical studies found that lab animals fed raw wheat bran have fewer aberrant colonic crypt cells. These cells are thought to be pre- cancerous, and no one knows exactly how raw bran reduces their formation. The ARS scientists are experi- menting with samples of bran pro- cessed ...

All-Ireland cancer statistics 1994-96 43 Colon 6. MALIGNANT CANCER OF THE COLON ICD-O.2 C18 ICD-10 C18 ICD-9 153 This site includes the colon , from caecum and appendix to sigmoid colon , but excludes the rectosigmoid junction and overlapping tumours of colon and rectum. See also Chapters 5 (colorectal cancer , including all sites from colon to anus) and 7 (anorectal cancer ). Key facts • Average of 1702 new cases per year, 1994-96: 826 in females, 876 in males. • Average of 1025 deaths per year: 490 in females, 535 in males. • Age-standardised rates higher in males than females, by about 38% (incidence), about 51% (mortality). • 3rd most common site for cancer incidence in females, 4th most common in males. • 3rd most common cause of cancer deaths in both sexes. • Higher incidence rates in Northern Ireland (NI) ...

Colon Cancer (Page 1 of 3) ADJUVANT THERAPY PRIMARY TREATMENT PATHOLOGIC FINDINGS INITIAL EVALUATION* CLINICAL PRESENTATION PATHOLOGIC STAGE Completely removed CIS Adenomatous polyp with noninvasive carcinoma (CIS) Adenomatous polyp with invasive cancer Ulcerative/invasive nonobstructing lesion Residual adenoma Repeat colonoscopy immediately Surveillance Resectable Unresectable Stage I T1-2 N0 M0 Stage II T3-4 N0 M0 Poorly differentiated or fragmented specimen or T2 or greater or lymph or vascular invasion or residual lesion or mass T1, margins negative well or moderately differentiated, no lymph or vascular invasion, and no residual lesion or mass Stage III T1-3 N1-2 M0 Stage III T4 ...

[ CANCER RESEARCH 61, 632–640, January 15, 2001] Expression of Estrogen Receptor (ER) Subtypes and ER Isoforms in Colon Cancer 1 Martha Campbell-Thompson, 2 I. Jeanette Lynch, and Bhavna Bhardwaj Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida 32610 ABSTRACT Colon cancer incidence and mortality rates are lower in females com- pared with males, and numerous epidemiological studies suggest that estrogen replacement therapy (ERT) reduces cancer risk in postmeno- pausal women. Two estrogen receptor (ER) subtypes, ER and ER , mediate genomic effects in target cells. The aim of this study was to determine the relative mRNA expression levels for ER subtypes and ER isoforms in colon tumors, normal colonic mucosa, and colon cancer cell lines. ER and ER isoform mRNA levels were investigated ...